首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >A rational pharmacotherapeutic study of comparative safety among topical anti-acne 1% nadifloxacin monotherapy, 0.1% adapalene monotherapy, 0.025% tretinoin monotherapy, 1% nadifloxacin and 0.1% adapalene combination therapy and 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne vulgaris, in tertiary care hospitals
【24h】

A rational pharmacotherapeutic study of comparative safety among topical anti-acne 1% nadifloxacin monotherapy, 0.1% adapalene monotherapy, 0.025% tretinoin monotherapy, 1% nadifloxacin and 0.1% adapalene combination therapy and 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne vulgaris, in tertiary care hospitals

机译:轻度至中度局部抗痤疮1%纳地沙星单药,0.1%阿达帕林单药,0.025%维甲酸单药,1%纳地沙星和0.1%阿达帕林联合疗法以及1%纳地沙星和0.025%维甲酸联合治疗之间的相对安全性的合理药物治疗研究中度寻常痤疮,在三级护理医院

获取原文
           

摘要

Background: Topical adapalene and tretinoin, are comedolytic, anti-comedogenic and anti-inflammatory, on RAR (α, β, γ) receptors binding. Adapalene enables quicker follicular penetration, by lesser anti-AP-1 (c-Jun, c-Fos) and no CRBPII mRNA actions, causing chemical stability, lipophilicity and less photo-lability, producing lesser photosensitivity and no skin irritation, unlike tretinoin; wherein reducible by overnight application and combination therapy, slow-release polymers or emollients, respectively. Topical nadifloxacin is bactericidal, anti-inflammatory and comedolytic, with inhibitory effect on DNA gyrase, DNA topoisomerase IV and IL-1α, IL-6, IL-8. The Global Alliance to Improve Outcomes in Acne Guidelines recommend synergistic and additive combination therapies, which enhance therapeutic efficacy and reduce adverse effects. Due to inadequacy of data, this study was conducted, to compare the safety among topical anti-acne monotherapies and combination therapies, and to easily detect any adverse effect producing component in the topical combination therapy. Methods: In this multi-centre, prospective, randomised, open-labelled, comparative study, groups A, B, C, D and E (20 patients each), applied topical 1% nadifloxacin monotherapy, 0.1% adapalene monotherapy, 0.025% tretinoin monotherapy, 1% nadifloxacin and 0.1% adapalene combination therapy and 1% nadifloxacin and 0.025% tretinoin combination therapy, respectively, over their facial mild to moderate acne lesions, once daily overnight; and adverse effects, like erythema, scaling, dryness, prutitus, burning, or stinging, were assessed on 0, 15, 30, 60, 90 days and follow-ups, by Local Irritation Scale. Results: In all 5 groups, no adverse effects were observed, with no statistically significant difference among the observations. Conclusions: The therapies were well tolerated and safe among all 5 groups.
机译:背景:局部使用的阿达帕林和维A酸,在RAR(α,β,γ)受体结合上具有粉刺,抗粉刺和抗炎作用。与维甲酸不同,阿达帕林通过较少的抗AP-1(c-Jun,c-Fos)和没有CRBPII mRNA的作用而使卵泡更快地渗透,从而引起化学稳定性,亲脂性和较少的光不稳定,产生较小的光敏性和皮肤刺激性。其中通过过夜施用和联合治疗可分别减少缓释聚合物或润肤剂。局部纳迪沙星具有杀菌,抗炎和粉刺作用,对DNA促旋酶,DNA拓扑异构酶IV和IL-1α,IL-6,IL-8具有抑制作用。全球改善痤疮结果指南指南建议采用协同和加成联合治疗,以增强治疗效果并减少不良反应。由于数据不足,进行了这项研究,以比较局部抗痤疮单一疗法和联合疗法之间的安全性,并容易地检测局部联合疗法中产生任何不利影响的成分。方法:在这项多中心,前瞻性,随机,开放标签的比较研究中,A,B,C,D和E组(各20例)应用局部1%纳地沙星单药,0.1%阿达帕林单药,0.025%维甲酸在面部轻度至中度痤疮病变上,每天一次,每晚一次,分别采用单一疗法,1%纳地沙星和0.1%阿达帕林联合疗法以及1%纳地沙星和0.025%维甲酸联合疗法。根据局部刺激量表,在0、15、30、60、90天和随访时评估不良反应,如红斑,脱屑,干燥,阴蒂,灼热或刺痛。结果:在所有5组中,均未观察到不良反应,各观察结果之间无统计学差异。结论:所有5组患者的治疗耐受性良好且安全。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号